PDS Biotechnology’s (PDSB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $21.00 price objective on the stock.

PDSB has been the topic of several other reports. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, PDS Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $12.33.

PDS Biotechnology Trading Down 0.5 %

Shares of NASDAQ PDSB opened at $2.00 on Friday. The company has a market cap of $73.64 million, a price-to-earnings ratio of -1.72 and a beta of 1.93. PDS Biotechnology has a 12-month low of $1.53 and a 12-month high of $6.68. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock’s 50 day simple moving average is $3.19 and its 200 day simple moving average is $3.25.

Institutional Trading of PDS Biotechnology

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the last quarter. Geode Capital Management LLC raised its holdings in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after buying an additional 37,142 shares in the last quarter. Inspirion Wealth Advisors LLC raised its holdings in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after buying an additional 4,917 shares in the last quarter. Blair William & Co. IL raised its holdings in PDS Biotechnology by 204.4% during the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after buying an additional 81,743 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after buying an additional 47,528 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.